Issued on behalf of Aleen Inc.
VANCOUVER – Baystreet.ca News Commentary – Healthcare providers are prioritizing preventive care strategies as nearly 58% now integrate biomarker testing into early wellness indicators[1], a shift that comes as the hyper-personalized medicine market surges toward $3.18 trillion in 2025[2]. The combination of artificial intelligence, real-time wellness monitoring, and non-clinical data interpretation is transforming how individuals gain insights into their daily well-being and take early, awareness-focused action. Companies pioneering this transformation include Aleen Inc. (CSE: ALEN-U) a Canadian digital wellness company, Hims & Hers Health, Inc. (NYSE: HIMS), Butterfly Network, Inc. (NYSE: BFLY), Tempus AI, Inc. (NASDAQ: TEM), and Whitehawk Therapeutics, Inc. (NASDAQ: WHWK).
The momentum reflects healthcare and wellness leaders investing in AI and preventive care to strengthen financial sustainability despite current underinvestment by most systems[3]. New research demonstrates that analyzing three biomarkers together can identify cardiovascular risk nearly three times earlier than conventional methods[4], validating the shift toward multi-factor preventive assessment that positions data-driven platforms for accelerated adoption across clinical and consumer markets.
Aleen Inc. (CSE: ALEN-U), a Canadian technology company operating in the digital wellness space, has completed its initial concept testing for the upcoming Smart Analytics feature. The research highlighted three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over any information they choose to share, and simple, non-medical interpretation of structured inputs. These findings confirm Aleen Inc.'s focus on balance between clarity, autonomy, and usability as the company continues developing responsible, insight-based technologies that help users stay informed about their well-being without replacing professional consultation.
The company previously announced it was beginning early concept testing for smart wellness analytics, building on its initiative to enhance personalized interpretation of wellness information. "Our current focus is on understanding how an analytical tool can responsibly support everyday well-being --- while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen Inc. "We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions."
Based in Ontario, Aleen Inc. went public on the Canadian Securities Exchange in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The testing phase focused on assessing real user needs and expectations, exploring potential analytical approaches that could simplify recognition of trends over time, and conducting scenario-based evaluations to understand how structured insights might enhance personal well-being awareness.
Aleen Inc. operates in a rapidly expanding market. The global digital wellness sector is currently valued at approximately $12.87 billion in 2025 and is projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.'s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen Inc. plans to launch personal user accounts that will allow individuals to securely store and organize their wellness information in one place, alongside introducing the smart analytics features currently in testing. To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment. The company plans to allocate 35% of these funds toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
Hims & Hers Health, Inc. (NYSE: HIMS) has launched Labs, a holistic testing experience that provides customers with comprehensive biomarker analysis and doctor-developed action plans to proactively manage their health. The platform offers two tiers with Base providing 50 biomarker tests across nine categories for $199 annually and Advanced delivering over 120 biomarker tests across 10 categories for $499 annually, addressing the critical gap in preventive healthcare access given that 70% of medical decisions depend on lab tests.
"Truly transformational, preventive care has been out of reach for too many people for too long," said Andrew Dudum, CEO of Hims & Hers. "With Labs, we're bringing the benefits of data-driven, proactive healthcare to everyone. We're changing the status quo by making it simple to understand and act on results that matter for your long term health."
Labs empowers customers with insights across heart health, metabolism, hormones, inflammation and stress markers, with results paired to personalized treatment plans when deemed appropriate by healthcare providers. The company expects to expand the offering over time with plans to introduce at-home testing devices, additional biomarker tests in areas like bone and brain health, and advanced diagnostics that detect chronic and life-threatening conditions.
Butterfly Network, Inc. (NYSE: BFLY) has launched the world's first AI-powered blind-sweep Gestational Age calculator integrated directly into its app, now being used by clinicians in Malawi and Uganda to improve maternal and fetal health outcomes. The tool empowers lower-skilled healthcare workers to quickly and accurately calculate gestational age without requiring image interpretation or training, addressing the critical access gap in regions where 92% of all maternal and neonatal mortality rates occur.
"We are committed to expanding obstetric POCUS adoption in low-resource settings and ultimately improving outcomes for mothers and babies," said Dr. Sachita Shah, Vice President of Global Health at Butterfly Network. "Our AI-powered gestational age tool is an accurate, fast and simple way for lower skilled healthcare workers in SSA to get expecting women the right care plans for the stage of their pregnancy journey. Additionally, the model was trained using data from African populations in an effort to ensure relevance and high-quality performance."
The launch comes as Butterfly celebrates milestone achievements from its 1,000 Probe Partnership, which deployed 1,000 iQ+ handheld ultrasound probes and trained over 1,050 healthcare providers across Sub-Saharan Africa from September 2022 to December 2024, resulting in 1.8 million scans averaging 83,000 monthly. Preliminary data from the Clinton Health Access Initiative in South Africa shows a 1.13% decrease in stillbirths and 20.6% decrease in maternal mortality in the 12 months following training, with the newest Butterfly device, iQ3, now approved for use in South Africa and Kenya.
Tempus AI, Inc. (NASDAQ: TEM) has announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk's oncology pipeline. Under the agreement, Whitehawk will apply Tempus' de-identified multimodal database to support clinical trial designs by focusing on patient populations with the highest level of demonstrated real-world unmet need across Whitehawk's antibody drug conjugate portfolio targeting clinically validated proteins (PTK7, MUC16 and SEZ6) broadly expressed in lung and gynecological cancers.
"Tempus' comprehensive, multimodal data, paired with Whitehawk's ADC drug development expertise, create a powerful foundation to validate the potential of their portfolio in a promising class of targeted cancer therapeutics," said Ryan Fukushima, COO at Tempus. "We're committed to working in tandem with our biotech collaborators to uncover actionable insights from our AI platform so they can make smarter, faster decisions throughout the drug development process."
The collaboration centers on powering research spanning Whitehawk's three ADC assets designed to target high-potential cancer indications, with an emphasis on establishing concordance between RNA and IHC expression of therapeutic targets to enhance patient identification capabilities. Tempus' comprehensive AI platform and one of the world's largest libraries of multimodal data will enable Whitehawk to make data-driven decisions throughout indication prioritization for clinical development programs.
"A proactive approach to our biomarker strategy ensures our programs are guided by data-driven insights," said Dave Lennon, PhD, CEO of Whitehawk Therapeutics. "By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline. An important aspect of this partnership will be continuing to establish the concordance between RNA and IHC expression of our targets. Because RNA testing is objective, reproducible and scalable, establishing it as a reliable alternative to the more subjective IHC methods could enhance our ability to readily identify appropriate patients for our ADC therapies."
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
Baystreet.ca
cs@baystreet.ca
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition.
--
SOURCES CITED:
1. https://www.reanin.com/reports/metabolic-biomarker-testing-market
2. https://www.globenewswire.com/news-release/2025/11/04/3180551/0/en/Hyper-Personalized-Medicine-Market-Report-2025-2029-and-2034-Precision-Therapies-Propel-Growth-Genomic-Innovations-Drive-Breakthroughs-in-Personalized-Treatments.html
3. https://www.globenewswire.com/news-release/2025/11/03/3179110/0/en/New-Report-Reveals-Disconnect-Between-Short-Term-Focus-and-Long-Term-Data-Backed-Growth-Strategies-for-Health-Systems.html
https://newsroom.heart.org/news/analyzing-3-biomarker-tests-together-may-help-identify-high-heart-disease-risk-earlier
Related Stories
